The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson’s disease: Correlation with 18F-flurodeoxyglucose positron-emission tomography

Yoon, Ra Gyoung; Kim, Sang Joon; Kim, Ho Sung; Choi, Choong Gon; Kim, Jae Seung; Oh, Jungsu S.; Chung, Sun Ju; Lee, Chong Sik

doi:10.1016/j.neulet.2014.10.046

Cited by 34 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with atypical parkinsonism due to PSP and MSA often show putaminal changes using iron-sensitive MRI sequences to a degree that they are of significant diagnostic yield (Arabia et al 2010; Gupta et al 2010; Haller et al 2012, 2013; Wadia et al 2013; Feng et al 2015; Meijer et al 2015a; Yoon et al 2015; Barbagallo et al 2016; Sakurai et al 2017). SWI phase images were applied for the determination of different iron-deposition patterns in several grey nuclei in 16 patients with PD, 8 patients with MSA-P and 44 age-matched healthy controls (Wang et al 2012b).…”

Section: Exclusion Of Alternative Diagnosesmentioning

confidence: 99%

Magnetic resonance imaging for the diagnosis of Parkinson’s disease

et al. 2017

View full text Add to dashboard Cite

The differential diagnosis of parkinsonian syndromes is considered one of the most challenging in neurology and error rates in the clinical diagnosis can be high even at specialized centres. Despite several limitations, magnetic resonance imaging (MRI) has undoubtedly enhanced the diagnostic accuracy in the differential diagnosis of neurodegenerative parkinsonism over the last three decades. This review aims to summarize research findings regarding the value of the different MRI techniques, including advanced sequences at high- and ultra-high-field MRI and modern image analysis algorithms, in the diagnostic work-up of Parkinson’s disease. This includes not only the exclusion of alternative diagnoses for Parkinson’s disease such as symptomatic parkinsonism and atypical parkinsonism, but also the diagnosis of early, new onset, and even prodromal Parkinson’s disease.

show abstract

Section: Exclusion Of Alternative Diagnosesmentioning

confidence: 99%

Magnetic resonance imaging for the diagnosis of Parkinson’s disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…This is important in MSA, as several histopathological studies have revealed increased iron and ferritin levels in the putamen (particularly posteriorly), striatum and substantia nigra [44], and at a significantly higher amount than in IPD [45]. SWI studies have shown a much higher iron deposition in the putamen and pallidum of MSA-P compared to IPD and PSP [46, 47]. One study splitting the putamen into four regions suggested that the lower inner part is the best marker to differentiate between MSA-P and IPD [48].…”

Section: Measures Of Signal Changementioning

confidence: 99%

An update on advances in magnetic resonance imaging of multiple system atrophy

et al. 2018

View full text Add to dashboard Cite

In this review, we describe how different neuroimaging tools have been used to identify novel MSA biomarkers, highlighting their advantages and limitations. First, we describe the main structural MRI changes frequently associated with MSA including the ‘hot cross-bun’ and ‘putaminal rim’ signs as well as putaminal, pontine, and middle cerebellar peduncle (MCP) atrophy. We discuss the sensitivity and specificity of different supra- and infratentorial changes in differentiating MSA from other disorders, highlighting those that can improve diagnostic accuracy, including the MCP width and MCP/superior cerebellar peduncle (SCP) ratio on T1-weighted imaging, raised putaminal diffusivity on diffusion-weighted imaging, and increased T2* signal in the putamen, striatum, and substantia nigra on susceptibility-weighted imaging. Second, we focus on recent advances in structural and functional MRI techniques including diffusion tensor imaging (DTI), resting-state functional MRI (fMRI), and arterial spin labelling (ASL) imaging. Finally, we discuss new approaches for MSA research such as multimodal neuroimaging strategies and how such markers may be applied in clinical trials to provide crucial data for accurately selecting patients and to act as secondary outcome measures.

show abstract

“…A meta-analysis of 39 voxel-based morphometry studies of PD, MSA-P, CBD, and PSP has indicated that there are patterns of atrophy that can differentiate these disorders from each other (Yu et al, 2015). Other recent structural MRI studies not included in this meta-analysis were a volumetric study of the midbrain tegmentum to differentiate PD versus PSP (Kim et al, 2015); a support vector machine learning algorithm for classification of PD, PSP, and healthy controls using T1-weighted MRI (Salvatore et al, 2014); and susceptibility weighted imaging of the putamen to differentiate PD and MSA-P (Yoon et al, 2015). DTI also has potential for differentiating PD from atypical parkinsonian syndromes (Cherubini et al, 2014; Haller et al, 2012; Prodoehl et al, 2013) (Table 3).…”

Section: Neuroimaging Of Pdmentioning

confidence: 99%

Neuroimaging of Parkinson's disease: Expanding views

Weingarten

Sundman

Hickey

et al. 2015

Neuroscience & Biobehavioral Reviews

130

View full text Add to dashboard Cite

Advances in molecular and structural and functional neuroimaging are rapidly expanding the complexity of neurobiological understanding of Parkinson’s disease (PD). This review article begins with an introduction to PD neurobiology as a foundation for interpreting neuroimaging findings that may further lead to more integrated and comprehensive understanding of PD. Diverse areas of PD neuroimaging are then reviewed and summarized, including positron emission tomography, single photon emission computed tomography, magnetic resonance spectroscopy and imaging, transcranial sonography, magnetoencephalography, and multimodal imaging, with focus on human studies published over the last five years. These included studies on differential diagnosis, co-morbidity, genetic and prodromal PD, and treatments from L-DOPA to brain stimulation approaches, transplantation and gene therapies. Overall, neuroimaging has shown that PD is a neurodegenerative disorder involving many neurotransmitters, brain regions, structural and functional connections, and neurocognitive systems. A broad neurobiological understanding of PD will be essential for translational efforts to develop better treatments and preventive strategies. Many questions remain and we conclude with some suggestions for future directions of neuroimaging of PD.

show abstract

The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson’s disease: Correlation with 18F-flurodeoxyglucose positron-emission tomography

Cited by 34 publications

References 33 publications

Magnetic resonance imaging for the diagnosis of Parkinson’s disease

Magnetic resonance imaging for the diagnosis of Parkinson’s disease

An update on advances in magnetic resonance imaging of multiple system atrophy

Neuroimaging of Parkinson's disease: Expanding views

Contact Info

Product

Resources

About